The state of the fight: 

More European countries cautioned against Moderna’s vaccine for younger people over concerns about side effects.
  Generics companies are preparing to roll out their versions of Merck’s molnupiravir oral antiviral.
  Pfizer is in talks with 90 countries over supply deals for its antiviral candidate.



France and Germany recommended against the Moderna vaccine for people under 30 over concerns about…

The state of the fight: 

Merck will allow Medicines Patent Pool to sublicense its oral antiviral to manufacturers in 105 LMICs.
  The Access to COVID-19 Tools Accelerator released a new strategic plan and budget through September 2022.
  Antidepressant fluvoxamine reduced the risk of hospitalization for high-risk Covid-19 patients by about 32%. Approved or authorized vaccines

Two pediatric doses of Moderna’s mRNA-based vaccine given 28 days apart produced a “…

The state of the fight: 

Countries raced to order Merck’s molnupiravir antiviral after positive Phase 3 results.
  WHO released an independent strategic review of the Access to COVID-19 Tools Accelerator.
  SII plans to ship bulk substance for its Covishield vaccine to AstraZeneca in the U.K. when it resumes exports. Approved or authorized vaccines

European countries pause Moderna shots over myocarditis risk: Iceland, Finland, Norway and Sweden all announced…

Advocates for developing countries manufacturing their own pharmaceutical products received another boost after WHO’s annual World Health Assembly (held May 24-31) passed a resolution (led by Ethiopia) calling for strengthening local production of medical technologies.

The resolution urges WHO member states to “develop evidence-based holistic national and regional policies, financing mechanisms, strategies and plans of action and to explore appropriate mechanisms to support the…

The state of the hunt: 

WHO cleared Sinovac’s vaccine for emergency use.
  Gavi’s COVAX AMC funding summit exceeded its goals, securing $2.4 billion in commitments.
  India ordered 300 million doses of a yet-to-be-authorized Bio E vaccine candidate. Approved or authorized vaccines

Sinovac’s inactivated vaccine notched WHO Emergency Use Listing on Monday, leaving the shot, CoronaVac, eligible for supply through the COVAX Facility. Less-demanding storage requirements…

The state of the hunt:

Pfizer and BioNTech plan to seek authorization of their vaccine for adolescents age 12-15 after promising Phase 3 results.
  J&J agreed to supply up to 400 million doses of Janssen’s jab to the African Union.
  Serum Institute of India launched clinical trials of its version of the Novavax vaccine candidate.



Approved or authorized vaccines
New data show lower efficacy for Pfizer/BioNTech: The…